{
  "protocol": {
    "name": "Psilocybin-Assisted Therapy for Treatment-Resistant Depression",
    "version": "1.0",
    "therapy_type": "psilocybin_psychedelic",
    "condition_treated": "Treatment-Resistant Depression (TRD)",
    "evidence_level": "phase_3_clinical_trial",
    "overview": "Evidence-based psilocybin-assisted psychotherapy protocol based on COMP360 Phase 3 trials and Johns Hopkins University research. Integrates psychological support with controlled psilocybin administration for major depressive disorder unresponsive to at least two prior antidepressant trials.",
    "duration_weeks": 12,
    "total_sessions": 15,
    "evidence_sources": [
      "Goodwin GM, et al. N Engl J Med. 2022;387(18):1637-1648 (PMID: 36322843)",
      "Davis AK, et al. JAMA Psychiatry. 2021;78(5):481-489 (PMID: 33146667)",
      "Johnson MW, et al. J Psychopharmacol. 2008;22(6):603-620 (PMID: 18593734)",
      "Carhart-Harris RL, et al. Lancet Psychiatry. 2021;8(3):203-212 (PMID: 33545078)",
      "FDA Breakthrough Therapy Designation 2018",
      "COMP360 Phase 3 Trial Protocol (NCT03775200)"
    ]
  },
  "steps": [
    {
      "sequence_order": 1,
      "step_type": "screening",
      "title": "Comprehensive Psychiatric Evaluation",
      "description": "Detailed psychiatric assessment to confirm treatment-resistant depression diagnosis, assess eligibility, and establish baseline mental health status. Requires documented failure of at least two adequate antidepressant trials.",
      "duration_minutes": 90,
      "required_roles": ["psychiatrist", "clinical_psychologist"],
      "clinical_scales": [
        "MADRS (Montgomery-Åsberg Depression Rating Scale) - Primary outcome measure",
        "PHQ-9 (Patient Health Questionnaire-9)",
        "GAD-7 (Generalized Anxiety Disorder-7)",
        "QIDS-SR-16 (Quick Inventory of Depressive Symptomatology)",
        "Sheehan Disability Scale (SDS)",
        "WHO Quality of Life-BREF"
      ],
      "diagnostic_criteria": {
        "depression_severity": "MADRS score ≥ 20 (moderate to severe depression)",
        "trd_definition": "Failed at least 2 adequate trials (≥6 weeks, therapeutic dose) of antidepressants",
        "current_episode_duration": "≥ 4 weeks"
      },
      "documentation_requirements": {
        "psychiatric_history": [
          "Detailed depression history and timeline",
          "Prior antidepressant trials with doses, durations, responses",
          "Previous psychiatric hospitalizations",
          "Suicide attempt history",
          "Other mental health diagnoses",
          "Substance use history including psychedelics"
        ],
        "current_medications": [
          "All psychiatric medications with doses",
          "Non-psychiatric medications",
          "Supplements and herbals",
          "Recreational drug use"
        ],
        "suicide_risk_assessment": [
          "Columbia-Suicide Severity Rating Scale (C-SSRS)",
          "Current suicidal ideation and intent",
          "Access to means",
          "Protective factors",
          "Safety planning needs"
        ]
      }
    },
    {
      "sequence_order": 2,
      "step_type": "screening",
      "title": "Medical Clearance & Safety Screening",
      "description": "Comprehensive medical evaluation to identify contraindications and ensure patient safety for psilocybin administration. Focus on cardiovascular, neurological, and metabolic health.",
      "duration_minutes": 60,
      "required_roles": ["physician", "nurse_practitioner"],
      "vitals_monitoring": {
        "required": ["blood_pressure", "heart_rate", "temperature", "weight", "height", "bmi"]
      },
      "lab_tests_required": [
        "Complete Blood Count (CBC)",
        "Comprehensive Metabolic Panel (CMP)",
        "Thyroid Function Tests (TSH, Free T4)",
        "Electrocardiogram (ECG) - especially if age >40 or cardiac risk factors",
        "Pregnancy test (for women of childbearing potential)",
        "Urine drug screen"
      ],
      "medical_history_focus": [
        "Cardiovascular disease history",
        "Seizure disorder history",
        "Liver or kidney disease",
        "Uncontrolled hypertension",
        "Personal or family history of psychotic disorders",
        "Current pregnancy or breastfeeding"
      ]
    },
    {
      "sequence_order": 3,
      "step_type": "decision_point",
      "title": "Safety & Eligibility Determination",
      "description": "Comprehensive evaluation of inclusion/exclusion criteria based on psychiatric and medical screening to determine patient eligibility for psilocybin-assisted therapy.",
      "duration_minutes": 30,
      "required_roles": ["psychiatrist", "study_physician"],
      "evaluation_rules": {
        "type": "safety_assessment",
        "absolute_contraindications": [
          {
            "condition": "psychotic_disorder_history",
            "description": "Personal history of schizophrenia, schizoaffective disorder, or psychotic disorder",
            "action": "exclude_from_treatment"
          },
          {
            "condition": "first_degree_relative_psychosis",
            "description": "First-degree family member with schizophrenia or psychotic disorder",
            "action": "exclude_from_treatment"
          },
          {
            "condition": "bipolar_type_1",
            "description": "Bipolar I disorder with history of manic episodes",
            "action": "exclude_from_treatment"
          },
          {
            "condition": "active_suicidal_intent",
            "description": "Current suicidal intent with plan or recent attempt (<6 months)",
            "action": "exclude_from_treatment"
          },
          {
            "condition": "severe_cardiovascular_disease",
            "description": "Uncontrolled hypertension (>140/90), recent MI (<6 months), unstable angina",
            "action": "exclude_from_treatment"
          },
          {
            "condition": "pregnancy_breastfeeding",
            "description": "Currently pregnant or breastfeeding",
            "action": "exclude_from_treatment"
          },
          {
            "condition": "seizure_disorder",
            "description": "History of seizures (except childhood febrile seizures)",
            "action": "exclude_from_treatment"
          },
          {
            "condition": "active_substance_dependence",
            "description": "Current moderate-severe substance use disorder (except tobacco, cannabis)",
            "action": "defer_until_resolved"
          }
        ],
        "medication_contraindications": [
          {
            "medication_class": "MAOIs",
            "description": "Monoamine oxidase inhibitors",
            "required_washout": "2 weeks",
            "reason": "Serotonin syndrome risk"
          },
          {
            "medication_class": "lithium",
            "description": "Lithium therapy",
            "required_washout": "Consult with psychiatrist; may need discontinuation",
            "reason": "Seizure risk potentiation"
          },
          {
            "medication_class": "antipsychotics",
            "description": "First or second generation antipsychotics",
            "required_action": "May attenuate psilocybin effects; consider tapering if clinically appropriate",
            "reason": "5-HT2A receptor antagonism"
          }
        ],
        "acceptable_concomitant_medications": [
          "SSRIs/SNRIs (may reduce psilocybin effects but not contraindicated in COMP360 trial)",
          "Benzodiazepines at stable doses (available as rescue medication)",
          "Sleep medications (if stable)",
          "Thyroid replacement",
          "Antihypertensives (if well-controlled)"
        ]
      },
      "branch_outcomes": [
        {
          "outcome_id": "eligible_for_treatment",
          "next_step": 4,
          "description": "Patient meets inclusion criteria, no absolute contraindications"
        },
        {
          "outcome_id": "excluded_safety",
          "next_step": "exit_protocol",
          "description": "Absolute contraindication present, refer to alternative treatments"
        },
        {
          "outcome_id": "conditional_eligible",
          "next_step": 4,
          "description": "Eligible after medication adjustment or washout period"
        }
      ]
    },
    {
      "sequence_order": 4,
      "step_type": "preparation",
      "title": "Preparation Session 1 - Therapeutic Alliance & Education",
      "description": "First psychological preparation session focused on building therapeutic rapport, education about psilocybin effects, and setting intentions. Critical for establishing trust and safety.",
      "duration_minutes": 90,
      "required_roles": ["therapist_facilitator", "co_facilitator"],
      "session_structure": {
        "therapeutic_alliance": [
          "Introduction to therapy team (primary therapist and co-facilitator)",
          "Discussion of therapist backgrounds and approach",
          "Patient sharing of depression history and personal story",
          "Establishing trust and comfort with therapy team",
          "Clarifying patient's goals and hopes for treatment"
        ],
        "education_components": [
          "Pharmacology of psilocybin (onset, peak, duration, metabolism)",
          "Expected psychological effects (perceptual changes, emotional intensity, ego dissolution)",
          "Physical effects (nausea, changes in temperature perception, altered proprioception)",
          "Safety measures during dosing session",
          "Role of therapists during session (non-directive support)",
          "Integration work importance"
        ],
        "set_and_setting_introduction": [
          "Concept of 'set' (mindset, intentions, expectations)",
          "Concept of 'setting' (physical environment, music, support)",
          "Tour of dosing room (if not already shown)",
          "Discussion of comfort measures (blankets, eyeshades, tissues)",
          "Introduction to curated music playlist"
        ],
        "addressing_concerns": [
          "Common fears (losing control, going crazy, bad trip)",
          "Reassurance about safety monitoring",
          "Discussion of 'challenging experiences' as potentially therapeutic",
          "Review of therapist support strategies"
        ]
      },
      "homework_assigned": [
        "Journaling about depression history and turning points",
        "Reflecting on intentions for treatment",
        "Writing about fears or concerns",
        "Optional: listening to sample music from dosing playlist"
      ]
    },
    {
      "sequence_order": 5,
      "step_type": "preparation",
      "title": "Preparation Session 2 - Intention Setting & Trust Surrender",
      "description": "Second preparation session focused on deepening therapeutic relationship, setting specific intentions, and introducing concepts of trust, surrender, and acceptance during the psilocybin experience.",
      "duration_minutes": 90,
      "required_roles": ["therapist_facilitator", "co_facilitator"],
      "session_structure": {
        "homework_review": [
          "Review journaling about depression and intentions",
          "Discuss insights or emotions that arose",
          "Identify themes or patterns"
        ],
        "intention_setting": [
          "Articulating specific intentions for psilocybin session",
          "Exploring what healing might look or feel like",
          "Identifying aspects of self or life to explore",
          "Framing intentions as open questions rather than demands",
          "Examples: 'Help me understand my depression', 'Show me what I need to see', 'Help me feel connection again'"
        ],
        "trust_surrender_acceptance": [
          "Philosophy of 'trusting, letting go, being open' (Johns Hopkins framework)",
          "Practicing acceptance of whatever arises",
          "Discussing resistance and how to work with it",
          "Concept of 'going toward' difficult emotions rather than avoiding",
          "Metaphors: surfing waves, river flowing, passenger not driver"
        ],
        "difficult_experience_preparation": [
          "Normalizing challenging moments during sessions",
          "Strategies: deep breathing, trusting the process, calling for therapist support",
          "Reassurance that difficult experiences often precede breakthroughs",
          "Discussion of physical comfort measures (removing eyeshades, sitting up, therapist holding hand)"
        ],
        "practical_preparation": [
          "What to wear (comfortable clothing)",
          "What to eat day before and morning of (light, healthy foods)",
          "What NOT to consume (alcohol, recreational drugs)",
          "Arrival time and session timeline",
          "Post-session pickup arrangements (cannot drive)"
        ]
      },
      "homework_assigned": [
        "Finalizing intentions (can write down and bring to session)",
        "Self-care practices (sleep, nutrition, stress reduction)",
        "Continued journaling if helpful"
      ]
    },
    {
      "sequence_order": 6,
      "step_type": "preparation",
      "title": "Preparation Session 3 - Final Preparation & Safety Review",
      "description": "Final preparation session before dosing, reviewing practical details, finalizing intentions, addressing any remaining concerns, and reinforcing trust in the process and therapy team.",
      "duration_minutes": 90,
      "required_roles": ["therapist_facilitator", "co_facilitator"],
      "session_structure": {
        "readiness_assessment": [
          "Check-in on emotional readiness",
          "Address any new concerns or fears",
          "Review of sleep quality, stress levels, life circumstances",
          "Ensure patient feels supported and prepared"
        ],
        "timeline_walkthrough": [
          "Step-by-step review of dosing day from arrival to departure",
          "Typical timeline: onset (30-45 min), peak (2-3 hours), gradual descent (3-4 hours), return (6-8 hours total)",
          "What therapists will be doing during session (present, observing, occasional check-ins)",
          "When and how to request support"
        ],
        "intention_refinement": [
          "Revisiting and refining intentions",
          "Balancing specific goals with openness to unexpected insights",
          "Encouraging curiosity and non-attachment to outcomes"
        ],
        "music_and_eyeshades": [
          "Importance of music as guide for journey",
          "Encouragement to keep eyeshades on (promotes introspection)",
          "Permission to adjust or remove if needed"
        ],
        "safety_review": [
          "Medical monitoring during session (vitals every 30 minutes)",
          "Therapists remain in room entire time",
          "Bathroom breaks (with assistance if needed)",
          "Rescue medication available if needed (benzodiazepine for severe distress)",
          "Emergency protocols"
        ],
        "post_session_expectations": [
          "Likely feeling tired, emotionally raw, or unusually open",
          "Importance of integration session next day",
          "Journaling or resting in evening",
          "Not processing alone - saving for integration"
        ]
      },
      "final_checklist": [
        "Confirm dosing day logistics (arrival time, transportation)",
        "Verify fasting instructions (no food 4 hours before, light breakfast okay)",
        "Medication check (continue or hold current medications as directed)",
        "Emergency contact information updated",
        "Informed consent re-confirmed"
      ]
    },
    {
      "sequence_order": 7,
      "step_type": "decision_point",
      "title": "Dose Determination",
      "description": "Clinical decision-making to determine optimal psilocybin dose based on patient factors, depression severity, anxiety level, prior psychedelic experience, and risk assessment. Based on COMP360 trial dosing.",
      "duration_minutes": 20,
      "required_roles": ["psychiatrist", "study_physician"],
      "evaluation_rules": {
        "type": "dose_calculation",
        "comp360_dosing_framework": {
          "therapeutic_doses_tested": ["25mg", "10mg (comparator)", "1mg (control)"],
          "primary_therapeutic_dose": "25mg psilocybin",
          "note": "COMP360 uses synthetic psilocybin; doses not equivalent to psilocybin mushrooms"
        },
        "johns_hopkins_dosing_framework": {
          "low_dose": "10-15mg (threshold effects, minimal perceptual changes)",
          "moderate_dose": "20-25mg (significant psychological effects)",
          "high_dose": "30mg (profound mystical-type experiences)",
          "note": "Higher doses associated with greater mystical experience and better depression outcomes"
        },
        "dose_selection_factors": [
          {
            "factor": "depression_severity",
            "considerations": [
              {"severity": "MADRS 20-29 (moderate)", "recommendation": "20-25mg may be appropriate"},
              {"severity": "MADRS ≥30 (severe)", "recommendation": "25mg standard dose"},
              {"severity": "MADRS ≥35 (very severe)", "recommendation": "25mg, consider 30mg with experience"}
            ]
          },
          {
            "factor": "anxiety_comorbidity",
            "considerations": [
              {"anxiety": "GAD-7 <10 (mild)", "recommendation": "Standard dosing appropriate"},
              {"anxiety": "GAD-7 10-14 (moderate)", "recommendation": "May need more preparation but standard dose"},
              {"anxiety": "GAD-7 ≥15 (severe)", "recommendation": "Consider lower initial dose (20mg) or enhanced support"}
            ]
          },
          {
            "factor": "prior_psychedelic_experience",
            "considerations": [
              {"experience": "Naive", "recommendation": "Standard protocol, potentially start 20-25mg"},
              {"experience": "Some recreational use", "recommendation": "25mg standard dose"},
              {"experience": "Extensive experience", "recommendation": "25-30mg, higher dose may be beneficial"},
              {"experience": "Prior difficult experience", "recommendation": "Address in preparation, may reduce initial dose"}
            ]
          },
          {
            "factor": "body_weight",
            "note": "COMP360 used fixed dosing (not weight-based), but some protocols consider weight",
            "considerations": [
              {"weight_range": "<60kg", "consideration": "Standard dose appropriate, monitor closely"},
              {"weight_range": "60-90kg", "consideration": "Standard dose 25mg"},
              {"weight_range": ">90kg", "consideration": "Standard dose, may consider 30mg if other factors support"}
            ]
          },
          {
            "factor": "psychological_resilience",
            "considerations": [
              "History of handling stress and emotions",
              "Support system quality",
              "Capacity for introspection",
              "Motivation and commitment to process"
            ]
          }
        ],
        "standard_protocol": {
          "first_session_dose": "25mg psilocybin (COMP360 standard)",
          "second_session_dose": "Same or adjusted based on first session response",
          "third_session_dose": "If needed, adjusted based on response pattern"
        }
      },
      "branch_outcomes": [
        {
          "outcome_id": "dose_20mg",
          "next_step": 8,
          "description": "Conservative initial dose for higher anxiety or first-time psychedelic use"
        },
        {
          "outcome_id": "dose_25mg",
          "next_step": 8,
          "description": "Standard therapeutic dose based on COMP360 trial evidence"
        },
        {
          "outcome_id": "dose_30mg",
          "next_step": 8,
          "description": "Higher dose for severe depression or experienced individuals"
        }
      ]
    },
    {
      "sequence_order": 8,
      "step_type": "intervention",
      "title": "Psilocybin Dosing Session (Day 0)",
      "description": "Full-day supervised psilocybin administration in controlled clinical setting with continuous psychological support and medical monitoring. Duration typically 8-10 hours from arrival to discharge.",
      "duration_minutes": 480,
      "required_roles": ["psychiatrist", "therapist_facilitator", "co_facilitator", "nurse", "physician_on_call"],
      "pre_session_preparation": {
        "arrival_and_check_in": {
          "time": "Morning (typically 8-9 AM)",
          "activities": [
            "Greeting and settling into dosing room",
            "Review of intentions and any last questions",
            "Vital signs assessment (baseline)",
            "Urine drug screen (if required by protocol)",
            "Pregnancy test (if applicable)",
            "Final consent confirmation",
            "Review of comfort with therapists and setting"
          ]
        },
        "baseline_assessments": {
          "time": "30 minutes before dosing",
          "measures": [
            "Blood pressure, heart rate, temperature",
            "Brief psychiatric assessment (mood, anxiety)",
            "MADRS quick check",
            "Medical clearance confirmation"
          ]
        }
      },
      "dosing_protocol": {
        "administration_time": "Approximately 9:00-10:00 AM",
        "medication_form": "Psilocybin capsules (COMP360) or synthetic psilocybin solution",
        "administration_method": "Oral administration with water",
        "co_medications": [
          "Anti-nausea medication may be offered (ondansetron 4-8mg) 30 min before",
          "Benzodiazepine available as rescue (lorazepam 1-2mg) for severe anxiety"
        ],
        "setting": {
          "room_design": "Comfortable, living room-like with couch/bed, soft lighting, aesthetic elements",
          "music": "Curated playlist (6-8 hours) - classical, world, ambient, emotionally evocative",
          "comfort_items": "Eyeshades, blankets, tissues, water, fresh flowers",
          "therapist_positioning": "Seated nearby, attentive but not intrusive presence"
        }
      },
      "session_timeline": {
        "onset_phase": {
          "timeframe": "T+0 to T+45 minutes",
          "patient_experience": "Subtle shifts in perception, possible nausea, mild anxiety or excitement",
          "therapist_actions": [
            "Gentle reassurance and presence",
            "Encourage patient to lie back, put on eyeshades, listen to music",
            "Minimal verbal interaction unless patient initiates",
            "Observe for early anxiety and provide calming presence"
          ],
          "vitals_monitoring": "Every 30 minutes"
        },
        "ascent_phase": {
          "timeframe": "T+45 to T+120 minutes",
          "patient_experience": "Intensifying effects, visual phenomena, emotional waves, possible challenging content",
          "therapist_actions": [
            "Maintain supportive presence",
            "If patient shows distress: use reassuring touch (hand on shoulder), gentle words",
            "Reminders: 'trust, let go, be open', 'go toward it, not away'",
            "Encourage keeping eyeshades on for deeper introspection",
            "Minimal conversation - allow internal journey"
          ],
          "vitals_monitoring": "Every 30 minutes (BP, HR, temp)"
        },
        "peak_phase": {
          "timeframe": "T+120 to T+240 minutes (2-4 hours)",
          "patient_experience": "Peak intensity, possible mystical experience, ego dissolution, profound insights, emotional catharsis",
          "therapist_actions": [
            "Remain quietly present",
            "One therapist in room at all times, both during peak if possible",
            "Non-directive support - mirror patient's emotional state without interpreting",
            "If patient speaks: active listening, reflection, minimal guidance",
            "Support bathroom breaks if needed (assist walking if unsteady)",
            "Track any significant utterances or insights for later integration",
            "Manage challenging experiences with calm, grounding presence"
          ],
          "vitals_monitoring": "Every 30 minutes",
          "special_monitoring": [
            "Psychological state (anxiety, confusion, distress level)",
            "Need for intervention or rescue medication",
            "Safety awareness (patient staying on couch/bed, not leaving room)"
          ]
        },
        "descent_phase": {
          "timeframe": "T+240 to T+360 minutes (4-6 hours)",
          "patient_experience": "Gradual reduction in intensity, integration of experience beginning, emotional processing",
          "therapist_actions": [
            "Continue supportive presence",
            "May begin gentle check-ins: 'How are you feeling?'",
            "Allow patient to remove eyeshades when ready",
            "Offer water, light snacks if patient interested",
            "Begin gentle grounding (noticing room, physical sensations)",
            "Listen to patient's initial reflections without interpretation"
          ],
          "vitals_monitoring": "Every 30-60 minutes"
        },
        "return_phase": {
          "timeframe": "T+360 to T+480 minutes (6-8 hours)",
          "patient_experience": "Mostly returned to baseline, may feel tired, emotionally open, vulnerable, or peaceful",
          "therapist_actions": [
            "Check-in conversation about experience",
            "Ask open questions: 'What stands out?', 'How do you feel?'",
            "Reassurance and normalization",
            "Encourage journaling if patient feels ready",
            "Prepare for discharge and next-day integration",
            "Review self-care instructions for evening"
          ],
          "vitals_monitoring": "Final assessment before discharge",
          "discharge_criteria": [
            "Vital signs stable and near baseline",
            "Patient alert and oriented",
            "No acute psychological distress",
            "Safe transportation arranged (cannot drive)",
            "Patient understands post-session care instructions"
          ]
        }
      },
      "vitals_monitoring": {
        "required": ["blood_pressure", "heart_rate", "temperature", "respiratory_rate"],
        "frequency": "Every 30 minutes throughout session",
        "alert_parameters": {
          "systolic_bp": "> 180 or < 90 mmHg",
          "diastolic_bp": "> 110 or < 50 mmHg",
          "heart_rate": "> 120 or < 50 bpm",
          "temperature": "> 38.5°C (101.3°F)",
          "action_if_abnormal": "Physician evaluation, consider rescue medication or medical intervention"
        }
      },
      "rescue_protocols": {
        "psychological_distress": {
          "mild_anxiety": "Verbal reassurance, hand holding, grounding techniques",
          "moderate_distress": "Therapist speaking directly, physical comfort, reminding of safety",
          "severe_distress": "Benzodiazepine (lorazepam 1-2mg PO or IM), physician evaluation, trip-sitting until resolution"
        },
        "medical_emergency": {
          "procedures": "Emergency medical kit available, physician on-call, protocol for 911 if needed",
          "rare_complications": "Seizure, cardiovascular event, severe hypertension"
        }
      },
      "therapist_documentation": {
        "session_notes": [
          "Timeline of effects",
          "Behavioral observations",
          "Emotional expressions",
          "Significant statements or insights",
          "Interventions provided",
          "Challenging moments and how resolved",
          "Overall character of session"
        ],
        "scales": [
          "5D-ASC (5-Dimensional Altered States of Consciousness) - administered next day",
          "MEQ30 (Mystical Experience Questionnaire) - administered next day"
        ]
      },
      "post_session_care": {
        "evening_instructions": [
          "Rest at home with trusted person present",
          "Light, healthy dinner",
          "Journaling if desired, but no pressure to process",
          "No alcohol or recreational drugs",
          "Early bedtime encouraged",
          "Contact emergency number if any concerns"
        ],
        "next_day": "Integration session scheduled (typically 10-11 AM following day)"
      }
    },
    {
      "sequence_order": 9,
      "step_type": "followup",
      "title": "Integration Session 1 - Day After Dosing (Day 1)",
      "description": "Critical first integration session occurring 1 day after psilocybin dosing to process experience, capture insights, address emotional responses, and begin translating experience into actionable changes.",
      "duration_minutes": 90,
      "required_roles": ["therapist_facilitator", "co_facilitator"],
      "session_structure": {
        "check_in": [
          "How did you sleep?",
          "How do you feel physically and emotionally this morning?",
          "Any lingering effects or unusual experiences?",
          "Overall sense of the experience in retrospect?"
        ],
        "experience_review": [
          "Open-ended invitation to share experience",
          "What stands out most prominently?",
          "Timeline exploration (what happened when)",
          "Challenging moments and how they were navigated",
          "Peak moments or breakthrough experiences",
          "Unexpected elements"
        ],
        "insight_identification": [
          "What did you learn or realize?",
          "Any perspectives that shifted?",
          "Messages or themes that emerged?",
          "Symbols, visions, or metaphors that feel meaningful?",
          "Connection to depression and healing?"
        ],
        "emotional_processing": [
          "What emotions came up during session?",
          "What emotions are present now?",
          "Any grief, relief, joy, confusion?",
          "Validating and normalizing all responses"
        ],
        "meaning_making": [
          "What does this experience mean to you?",
          "How does it relate to your depression journey?",
          "What feels different or new?",
          "Beginning to connect insights to daily life"
        ],
        "mystical_experience_assessment": [
          "Administer MEQ30 (Mystical Experience Questionnaire)",
          "Discuss any spiritual or transcendent aspects",
          "Normalize variety of experiences (mystical or psychological)"
        ],
        "altered_states_assessment": [
          "Administer 5D-ASC (5-Dimensional Altered States of Consciousness)",
          "Capture phenomenology of experience for clinical record"
        ]
      },
      "clinical_scales": [
        "MEQ30 (Mystical Experience Questionnaire) - predictive of outcomes",
        "5D-ASC (5-Dimensional Altered States of Consciousness)",
        "EBI (Emotional Breakthrough Inventory)"
      ],
      "homework_assigned": [
        "Continued journaling about experience and emerging insights",
        "Noticing any shifts in mood, perspective, or behavior",
        "Self-compassion practices",
        "Identifying one small change to implement based on insights"
      ]
    },
    {
      "sequence_order": 10,
      "step_type": "followup",
      "title": "Integration Session 2 - Week 1 Post-Dosing",
      "description": "Second integration session focusing on translating insights into behavioral changes, monitoring mood shifts, and supporting integration into daily life.",
      "duration_minutes": 60,
      "required_roles": ["therapist_facilitator"],
      "session_structure": {
        "mood_assessment": [
          "How has your mood been this week?",
          "Changes in energy, motivation, sleep, appetite?",
          "Administer PHQ-9, GAD-7",
          "Suicidal ideation check"
        ],
        "integration_deepening": [
          "Insights continuing to unfold?",
          "Revisiting challenging parts of experience",
          "Connecting experience to ongoing life",
          "Processing any difficult emotions arising"
        ],
        "behavioral_activation": [
          "Identifying concrete changes or actions from insights",
          "Setting small, achievable goals",
          "Reconnecting with values and meaningful activities",
          "Addressing barriers to change"
        ],
        "social_integration": [
          "Sharing experience with others (or choosing not to)",
          "Changes in relationships or social engagement?",
          "Re-entry into normal life and routines"
        ]
      },
      "clinical_scales": ["PHQ-9", "GAD-7"],
      "homework_assigned": [
        "Implementing one behavioral change from insights",
        "Mindfulness or meditation practice if interested",
        "Tracking mood daily"
      ]
    },
    {
      "sequence_order": 11,
      "step_type": "followup",
      "title": "Integration Session 3 - Week 2 Post-Dosing",
      "description": "Continued integration work with focus on sustaining changes, addressing challenges, and monitoring depression symptoms.",
      "duration_minutes": 60,
      "required_roles": ["therapist_facilitator"],
      "session_structure": {
        "progress_review": [
          "Mood and symptom tracking",
          "Behavioral changes implemented",
          "Challenges encountered",
          "Wins or positive shifts"
        ],
        "deeper_therapy": [
          "Using psilocybin insights for ongoing therapeutic work",
          "Addressing core beliefs or patterns revealed",
          "Trauma processing if relevant",
          "Relationship patterns or life direction"
        ],
        "sustaining_change": [
          "What's helping maintain positive changes?",
          "What threatens regression?",
          "Building new habits and routines",
          "Cultivating supports"
        ]
      },
      "clinical_scales": ["PHQ-9", "GAD-7"]
    },
    {
      "sequence_order": 12,
      "step_type": "followup",
      "title": "Week 3 Assessment - Clinical Outcome Evaluation",
      "description": "Comprehensive clinical assessment at 3 weeks post-dosing to evaluate treatment response and determine next steps.",
      "duration_minutes": 60,
      "required_roles": ["psychiatrist", "therapist_facilitator"],
      "clinical_scales": [
        "MADRS (primary outcome - administered by trained rater)",
        "PHQ-9",
        "GAD-7",
        "QIDS-SR-16",
        "Sheehan Disability Scale",
        "WHO Quality of Life-BREF",
        "C-SSRS (suicidality)"
      ],
      "assessment_focus": [
        "Depression severity compared to baseline",
        "Functional improvement",
        "Quality of life changes",
        "Sustained vs. temporary improvement",
        "Adverse effects or concerns",
        "Integration quality"
      ]
    },
    {
      "sequence_order": 13,
      "step_type": "decision_point",
      "title": "Treatment Response Evaluation & Second Session Decision",
      "description": "Clinical decision point to evaluate response to first psilocybin session and determine need for second dosing session. Based on COMP360 protocol which typically includes 1-3 sessions.",
      "duration_minutes": 30,
      "required_roles": ["psychiatrist", "study_physician"],
      "evaluation_rules": {
        "type": "treatment_response_assessment",
        "response_criteria": [
          {
            "category": "full_response",
            "definition": "MADRS reduction ≥50% from baseline OR MADRS score <10 (remission)",
            "clinical_significance": "Substantial improvement, depression in remission or near-remission",
            "recommendation": "Continue integration therapy, monitor closely, second session may not be immediately needed"
          },
          {
            "category": "partial_response",
            "definition": "MADRS reduction 25-49% from baseline",
            "clinical_significance": "Meaningful improvement but still symptomatic",
            "recommendation": "Schedule second psilocybin session, continue integration"
          },
          {
            "category": "minimal_response",
            "definition": "MADRS reduction <25% from baseline",
            "clinical_significance": "Limited benefit, still significantly depressed",
            "recommendation": "Schedule second session with possible dose adjustment, evaluate other factors"
          },
          {
            "category": "no_response",
            "definition": "No improvement or worsening",
            "clinical_significance": "Treatment not effective for this patient",
            "recommendation": "Consider alternative treatments, evaluate session quality, address barriers"
          }
        ],
        "timing_considerations": {
          "standard_protocol": "Second session typically 3-5 weeks after first session",
          "comp360_protocol": "Up to 3 sessions spaced weeks apart",
          "rationale": "Allow time for integration and assessment before re-dosing"
        },
        "dose_adjustment_for_second_session": [
          {
            "first_session_dose": "20mg",
            "first_session_response": "Good tolerance, partial response",
            "second_session_recommendation": "Increase to 25mg"
          },
          {
            "first_session_dose": "25mg",
            "first_session_response": "Good tolerance, partial response",
            "second_session_recommendation": "Continue 25mg or consider 30mg"
          },
          {
            "first_session_dose": "25mg",
            "first_session_response": "Excessive anxiety or poor tolerance",
            "second_session_recommendation": "Reduce to 20mg or enhance preparation"
          },
          {
            "first_session_dose": "30mg",
            "first_session_response": "Well-tolerated",
            "second_session_recommendation": "Continue 30mg"
          }
        ],
        "factors_affecting_decision": [
          "Quantitative symptom improvement (MADRS, PHQ-9)",
          "Quality of mystical experience (MEQ30 score - higher scores predict better outcomes)",
          "Quality of integration work",
          "Patient's subjective sense of benefit",
          "Tolerability and safety",
          "Patient preference and readiness",
          "Life circumstances and stability"
        ]
      },
      "branch_outcomes": [
        {
          "outcome_id": "schedule_second_session",
          "next_step": 14,
          "description": "Second psilocybin session recommended, return to preparation phase"
        },
        {
          "outcome_id": "continue_integration_only",
          "next_step": 15,
          "description": "Strong response, continue integration therapy without immediate re-dosing"
        },
        {
          "outcome_id": "consider_alternative_treatment",
          "next_step": "exit_protocol",
          "description": "Minimal benefit, explore other treatment options"
        }
      ]
    },
    {
      "sequence_order": 14,
      "step_type": "followup",
      "title": "Ongoing Integration Sessions (Weeks 4-12)",
      "description": "Weekly or bi-weekly integration therapy sessions to sustain and deepen therapeutic gains, process ongoing insights, and support behavioral changes.",
      "duration_minutes": 60,
      "required_roles": ["therapist_facilitator"],
      "session_frequency": "Weekly for weeks 4-8, then bi-weekly weeks 9-12 (adjust based on need)",
      "session_focus": [
        "Mood and symptom monitoring",
        "Behavioral activation and valued living",
        "Relationship improvements",
        "Processing trauma or difficult emotions revealed",
        "Mindfulness and self-compassion practices",
        "Relapse prevention and coping skills",
        "Life changes and goal-setting",
        "Preparing for treatment end and maintenance"
      ],
      "clinical_monitoring": {
        "frequency": "Every 2 weeks",
        "scales": ["PHQ-9", "GAD-7", "C-SSRS"],
        "purpose": "Track symptom trajectory and identify early relapse signs"
      }
    },
    {
      "sequence_order": 15,
      "step_type": "followup",
      "title": "End of Treatment Assessment (Week 12)",
      "description": "Comprehensive end-of-protocol assessment to evaluate overall outcomes, prepare for transition to maintenance care, and celebrate progress.",
      "duration_minutes": 90,
      "required_roles": ["psychiatrist", "therapist_facilitator"],
      "clinical_scales": [
        "MADRS (primary outcome)",
        "PHQ-9",
        "GAD-7",
        "QIDS-SR-16",
        "Sheehan Disability Scale",
        "WHO Quality of Life-BREF",
        "Patient Global Impression of Change (PGI-C)",
        "Clinical Global Impression (CGI-I)"
      ],
      "assessment_components": {
        "symptom_outcomes": [
          "Depression severity compared to baseline and week 3",
          "Remission status (MADRS <10)",
          "Response status (≥50% reduction)",
          "Anxiety symptoms",
          "Suicidal ideation",
          "Functional improvement",
          "Quality of life"
        ],
        "process_outcomes": [
          "Quality of therapeutic relationship",
          "Integration success",
          "Behavioral changes sustained",
          "Insights applied to daily life",
          "Patient satisfaction with treatment"
        ],
        "safety_outcomes": [
          "Adverse events throughout protocol",
          "Tolerability assessment",
          "Any concerning psychological reactions",
          "Physical health changes"
        ]
      },
      "transition_planning": {
        "if_in_remission": [
          "Monthly check-ins for 3-6 months",
          "Relapse prevention plan",
          "Early warning signs identification",
          "Coping strategies",
          "When to seek help",
          "Possibility of booster session if needed (6-12 months)"
        ],
        "if_partial_response": [
          "Continued integration therapy",
          "Consider third psilocybin session",
          "Adjunctive treatments (medication, other therapies)",
          "Ongoing monitoring"
        ],
        "if_non_response": [
          "Referral to alternative treatments",
          "Evaluation of treatment barriers",
          "Medication optimization",
          "Other evidence-based therapies (ECT, TMS, ketamine)"
        ]
      }
    }
  ],
  "ongoing_monitoring": {
    "follow_up_assessments": {
      "one_month_post_treatment": {
        "scales": ["MADRS", "PHQ-9", "GAD-7"],
        "purpose": "Assess durability of response"
      },
      "three_months_post_treatment": {
        "scales": ["MADRS", "PHQ-9", "GAD-7", "WHO-QOL"],
        "purpose": "Long-term outcome evaluation"
      },
      "six_months_post_treatment": {
        "scales": ["MADRS", "PHQ-9", "Relapse assessment"],
        "purpose": "Durability and relapse monitoring"
      }
    },
    "booster_sessions": {
      "indication": "Symptom re-emergence after initial response",
      "timing": "Typically not before 6 months after initial treatment",
      "protocol": "Abbreviated preparation (1-2 sessions) + dosing + integration"
    }
  },
  "safety_monitoring": {
    "absolute_contraindications": [
      "Personal history of psychotic disorder",
      "First-degree relative with schizophrenia",
      "Bipolar I disorder with manic episodes",
      "Immediate suicidal intent with plan",
      "Pregnancy or breastfeeding",
      "Unstable cardiovascular disease",
      "Seizure disorder (except childhood febrile seizures)"
    ],
    "relative_contraindications": [
      "Bipolar II disorder (proceed with caution)",
      "Controlled cardiovascular disease",
      "Severe anxiety (requires enhanced preparation)",
      "Current SSRI use (may reduce effects but not contraindicated)"
    ],
    "adverse_effects_monitoring": [
      {
        "effect": "Transient anxiety/paranoia during session",
        "frequency": "Common (20-30%)",
        "management": "Therapeutic support, rarely rescue benzodiazepine",
        "duration": "Resolves within session"
      },
      {
        "effect": "Nausea/vomiting",
        "frequency": "Common (10-20%)",
        "management": "Prophylactic ondansetron",
        "duration": "First 1-2 hours"
      },
      {
        "effect": "Headache",
        "frequency": "Occasional (5-10%)",
        "management": "Acetaminophen post-session",
        "duration": "1-2 days"
      },
      {
        "effect": "Emotional lability post-session",
        "frequency": "Common (30-40%)",
        "management": "Integration therapy, normalization",
        "duration": "Days to weeks"
      },
      {
        "effect": "Hallucinogen Persisting Perception Disorder (HPPD)",
        "frequency": "Very rare (<1%)",
        "management": "Reassurance, psychiatry follow-up, usually self-limiting",
        "duration": "Variable"
      },
      {
        "effect": "Prolonged psychological difficulty",
        "frequency": "Rare (1-2%)",
        "management": "Intensive integration therapy, psychiatric support, possible medication",
        "duration": "Weeks to months, typically resolves"
      }
    ],
    "emergency_protocols": {
      "severe_psychological_distress": "Benzodiazepine administration, psychiatric evaluation, possible hospitalization",
      "medical_emergency": "On-site physician, emergency medical services, hospital transfer",
      "suicidal_crisis": "Safety assessment, psychiatric hospitalization if needed, intensive follow-up"
    }
  },
  "special_populations": {
    "elderly_patients": {
      "considerations": [
        "More thorough cardiovascular screening",
        "May need more preparation sessions",
        "Enhanced support during session",
        "Careful medication interaction review"
      ]
    },
    "patients_with_trauma_history": {
      "considerations": [
        "Trauma-informed approach throughout",
        "Extended preparation focusing on safety and control",
        "Possible trauma re-experiencing during session (can be therapeutic)",
        "Trauma-focused integration therapy",
        "Collaboration with trauma specialist"
      ]
    },
    "patients_on_ssris_snris": {
      "considerations": [
        "May have blunted psilocybin response (serotonin receptor downregulation)",
        "Not contraindicated in COMP360 trial (most patients were on antidepressants)",
        "Consider higher dose or medication taper if appropriate",
        "No serotonin syndrome risk with psilocybin"
      ]
    }
  },
  "research_context": {
    "comp360_phase_3_results": {
      "primary_outcome": "MADRS reduction at week 3",
      "25mg_response_rate": "Approximately 37% remission (MADRS <10), 29% response (≥50% reduction)",
      "durability": "Effects sustained in many patients at 12 weeks",
      "comparison": "Superior to 1mg control, comparable to 10mg comparator dose"
    },
    "johns_hopkins_findings": {
      "mystical_experience_correlation": "Higher MEQ30 scores predict better depression outcomes",
      "dose_response": "Higher doses (20-30mg/70kg) more likely to produce therapeutic mystical experiences",
      "long_term_outcomes": "Many patients maintain improvement 6-12 months post-treatment"
    }
  },
  "clinical_pearls": [
    "Therapeutic relationship quality is critical - invest in preparation phase",
    "Music and setting profoundly influence experience - attend to details",
    "Challenging experiences during session often lead to breakthroughs - encourage acceptance",
    "Mystical experience quality predicts outcomes - support conditions for transcendent experience",
    "Integration is where healing happens - don't underestimate post-session therapy",
    "Safety screening is paramount - err on side of caution with contraindications",
    "Set and setting cannot be overemphasized - every detail matters"
  ]
}
